JGJudit García-Aparicio

Judit García-Aparicio

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Judit García-Aparicio has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact on Sleep Quality, Mood, Anxiety, and Personal Satisfaction of Doctors Assigned to COVID-19 Units

    by Pilar Andrés-Olivera, Judit García-Aparicio, María Teresa Lozano López, José Antonio Benito Sánchez, Carmen Martín, Ana Maciá-Casas, Armando González-Sánchez, Miguel Marcos, Carlos Roncero

    The SARS-CoV-2 health emergency has led to a restructuring of health care systems and the reassignment of medical specialists from their usual duties to attend COVID-19 patients. The aim of this paper is to describe the levels of insomnia, anxiety, depression, and the impact on quality of life of doctors who were on the frontline of COVID-19 during the first two waves of the pandemic. Self-report surveys were conducted on said physicians during both waves, with 83 and 61 responses in the first and second waves, respectively. The reported presence of insomnia was frequent (71.8%), although it decreased in the second survey. Anxiety was moderate, decreasing from 57.1% to 43.1% between measurements. Overall, depression rates decreased between the two surveys. Substance use was found to have an indirect correlation with personal and professional satisfaction. In the light of the unforeseeable evolution of the pandemic and the medium- to long-term repercussions on professionals, we believe the adaptation of health resources is crucial to meet the new unpredictable mental health needs of this group.


  • Open Access

    Date of Admission during COVID-19 Pandemic Impacted Patient Outcomes in Addition to the Higher Efficacy of Tocilizumab Plus High-Dose Corticosteroid Therapy Compared to Tocilizumab Alone

    by Moncef Belhassen-García, Antonio Sánchez-Puente, Pedro-Ignacio Dorado-Díaz, Amparo López-Bernús, Jesús Sampedro-Gómez, Raúl Azibeiro-Melchor, Edgard Marcano-Millán, Beatriz Rodríguez-Alonso, María-Elisa Sánchez-Barrado, Ignacio Hernández-García, et al.

    Background: The evidence for the efficacy of glucocorticoids combined with tocilizumab (TCZ) in COVID-19 comes from observational studies or subgroup analysis. Our aim was to compare outcomes between hospitalized COVID-19 patients who received high-dose corticosteroid pulse therapy and TCZ and those who received TCZ. Methods: A retrospective single-center study was performed on consecutive hospitalized patients with severe COVID-19 between 1 March and 23 April 2020. Patients treated with either TCZ (400–600 mg, one to two doses) and methylprednisolone pulses (MPD-TCZ group) or TCZ alone were analyzed for the occurrence of a combined endpoint of death and need for invasive mechanical ventilation during admission. The independence of both treatment groups was tested using machine learning classifiers, and relevant variables that were potentially different between the groups were measured through a mean decrease accuracy algorithm. Results: An earlier date of admission was significantly associated with worse outcomes regardless of treatment type. Twenty patients died (27.0%) in the TCZ group, and 33 (44.6%) died or required intubation (n = 74), whereas in the MPD-TCZ group, 15 (11.0%) patients died and 29 (21.3%) patients reached the combined endpoint (n = 136; p = 0.006 and p < 0.001, respectively). Machine learning methodology using a random forest classifier confirmed significant differences between the treatment groups. Conclusions: MPD and TCZ improved outcomes (death and invasive mechanical ventilation) among hospitalized COVID-19 patients, but confounding variables such as the date of admission during the COVID-19 pandemic should be considered in observational studies.

  • Polymorphisms in genes implicated in base excision repair (BER) pathway are associated with susceptibility to Paget's disease of bone

    by Ricardo Usategui-Martín, Carlos Gutiérrez-Cerrajero, Sonia Jiménez-Vázquez, Ismael Calero-Paniagua, Judit García-Aparicio, Luis Corral-Gudino, Javier del Pino-Montes, Rogelio González-Sarmiento


  • Medication errors detected in elderly patients admitted to an internal medicine service

    by J. García‐Aparicio, Herrero‐ Herrero, J. I.

    The aim of the work was to analyse the outpatient medication errors detected on admission in senior patients in a Spanish general internal medicine service. We carried out a retrospective cohort study based on a review of the admission reports of consecutive, non-selected, patients aged ≥ 65 years. Eight hundred and sixty admission reports (cases) were analysed. Overall, we detected 218 errors in 173 (20.1%) of them. 'Wrong drug' errors were found in 165 occasions (75.7% of the 218 detected errors), being the most frequent among these 'not indicated/inappropriate drug for the diagnosis' (61 cases, 28.0%), followed by 'not indicated/inappropriate drug for the patient's condition' (55 cases, 25.2%). The binary logistic regression analysis showed association (p<0.05) between medication errors and sex (female) (OR 0.53, 95%, CI 0.37-0.76), cognitive impairment (OR 0.57, 95% CI 0.38-0.85), length of hospital stay (OR 1.06, 95% CI 1.00-1.11), number of diagnoses (OR 0.92, 95% CI 0.85-0.98), number of medicines at admission (OR 1.20, 95% CI 1.13-1.28) and lack of a recent previous admission in an internal medicine department (OR 2.07, 95% CI 1.14-3.74). Although previous studies are not completely comparable, the incidence of errors found at admission in our study is low. We stress the relevance of the reconciliation of treatment in elderly people (where internists may play an important role, from their perspective of a comprehensive patient's care) and integrated procedures for medication prescription and dispensation.


  • [Monitoring of a protocol for the adequacy of the pharmaceutical form of the oral medication to the degree of dysphagia in patients hospitalized in an internal medicine service].

    by J García Aparicio, J I Herrero Herrero, A Ma Moreno Gómez, J Martínez Sotelo, E González Del Valle, Ma A Fernández De La Fuente

    The oral route is the most convenient way of administering medication, although it may not be safe. Dysphagia is one of the factors rendering difficult a proper feeding and administration of medication. to improve the administration of oral medication in patients with dysphagia by changing the pharmaceutical formulation of the principles prescribed to tolerable textures. Pilot project for the application of a dysphagia protocol that included the patients admitted to the Internal Medicine Unit at Los Montalvos Center for 4 months. After detecting the suspicion of dysphagia, a dysphagia-viscosity test was applied to know the tolerated textures. Then, the pharmaceutical formulations were adapted and the manipulation instructions for the drugs were indicated for their proper administration. 23 out of 627 admitted patients were included, with a mean age of 85 years (σ±7.4). The pathologies implicated in dysphagia were: dementia (65.2%); cerebrovascular disease (30.4%), and Parkinson's disease (4.4%). The best texture for drug intake was a "pudding" in 48.0%. 43 active ingredients were reviewed and 134 interventions were performed: in 41% of the cases, swallowing was made easier by mixing the drug with the food and in 59% water and a thickener were used. 94% of the recommendations were considered to be appropriate. the adaptation of the pharmaceutical formulations to the degree of dysphagia impacts on the improvement of healthcare quality by implementing safety in drug prescription and administration processes.


  • Corticosteroid Therapy in a Case of Severe Cholestasic Hepatitis Associated with Amoxicillin–Clavulanate

    by José-Ignacio Herrero-Herrero, Judit García-Aparicio

    Amoxicillin–clavulanate is the most common drug involved in drug-induced liver injury and the single most frequently prescribed product leading to hospitalization for drug-induced liver disease in Spain. The liver damage most frequently associated with amoxicillin–clavulanate is cholestasic type. The latency period between first intake and onset of symptoms is 3–4 weeks on average. A 76-year-old man developed fever, pruritus, and jaundice 3 weeks after having completed treatment with amoxicillin–clavulanate. Liver function tests showed cholestasic hepatitis (up to 50.75 mg/dL of total serum bilirubin level). The ultrasound-guided liver biopsy revealed severe canalicular cholestasis and portal and lobular eosinophilic infiltrates. Prednisone and ursodeoxycholic acid therapy were then prescribed. The patient became symptom-free with normal liver function tests. Amoxicillin–clavulanate can cause hepatocellular, cholestasic, or mixed liver injury. The presence of eosinophilic infiltrates in the liver biopsy and the clinical signs of hypersensitivity in some of the cholestasic cases suggest a pathophysiological immunoallergic mechanism. For this reason, corticosteroid treatment should be considered for patients with severe cholestasic liver injury.